MGMartin J. Glennie

Martin J. Glennie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Martin J. Glennie has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Mark Steven Cragg

    Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK

    4 shared publications
  • Alison L. Tutt

    Tenovus Research Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton

    3 shared publications
  • Peter W. M. Johnson

    Cancer Research UK Clinical Centre, University of Southampton, Southampton, UK

    3 shared publications
  • Jamie Honeychurch

    Lymphoma Research Unit, Tenovus Laboratory, General Hospital , Southampton

    2 shared publications
  • Adam F. Cunningham

    MRC Centre for Immune Regulation, Division of Immunity and Infection, University of Birmingham, Birmingham, UK

    1 shared publication
  • Aimée Smith

    From the Tenovus Research Laboratory, Cancer Sciences Division, School of Medicine, University of Southampton, United Kingdom; and the Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom

    1 shared publication

Latest Publications

  • Open Access

    LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation

    by Muchaala Yeboah, Charys Papagregoriou, Des C. Jones, H.T. Claude Chan, Guangan Hu, Justine S. McPartlan, Torbjörn Schiött, Ulrika Mattson, C. Ian Mockridge, Ulla-Carin Tornberg, et al.

    Despite advances in identifying the key immunoregulatory roles of many of the human leukocyte immunoglobulin-like receptor (LILR) family members, the function of the inhibitory molecule LILRB3 (ILT5, CD85a, LIR3) remains unclear. Studies indicate a predominant myeloid expression; however, high homology within the LILR family and a relative paucity of reagents have hindered progress toward identifying the function of this receptor. To investigate its function and potential immunomodulatory capacity, a panel of LILRB3-specific monoclonal antibodies (mAbs) was generated. LILRB3-specific mAbs bound to discrete epitopes in Ig-like domain 2 or 4. LILRB3 ligation on primary human monocytes by an agonistic mAb resulted in phenotypic and functional changes, leading to potent inhibition of immune responses in vitro, including significant reduction in T cell proliferation. Importantly, agonizing LILRB3 in humanized mice induced tolerance and permitted efficient engraftment of allogeneic cells. Our findings reveal powerful immunosuppressive functions of LILRB3 and identify it as an important myeloid checkpoint receptor.


  • Open Access

    247. OBINUTUZUMAB INDUCES SUPERIOR B CELL CYTOTOXICITY TO RITUXIMAB THROUGH FCγR-DEPENDENT AND -INDEPENDENT EFFECTOR MECHANISMS IN RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT SAMPLES

    by Venkat Reddy, David Isenberg, Christian Klein, Geraldine Cambridge, Martin Glennie, Mark Cragg, Maria Leandro

    Background: Incomplete B-cell depletion following treatment with rituximab, a chimeric Type I anti-CD20 monoclonal antibody (mAb), is associated with poor clinical responses in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), which can be augmented by delivering higher doses. Humanized type I anti-CD20 mAbs Ocrelizumab and/or Ofatumumab achieve comparable clinical responses to rituximab in RA and SLE suggesting that factors beyond human anti-chimeric antibodies such as defects in complement system, NK cells and macrophages may also contribute to inefficient B-cell depletion with rituximab, particularly in some patients with SLE. Further, internalisation may also impair the efficiency of rituximab-induced B-cell depletion. We hypothesized that mechanistically different Obinutuzumab, a Type II anti-CD20 mAb bearing afucosylated Fc portion may, at least partly, overcome disease-associated immune defects and outperform rituximab at inducing B-cell depletion in SLE.

  • Antibody Therapy in Oncology

    by Martin Glennie, Özlem Türeci, Peter W. M. Johnson

  • Novel antibodies targeting immune regulatory checkpoints for cancer therapy

    by Chern Siang Lee, Mark Cragg, Martin Glennie, Peter Johnson

    Cancers must evade or suppress the immune system in order to develop. Better understanding of the molecular regulation governing tumour detection and effective activation of the immune system (so called immune regulatory checkpoints) has provided new targets for cancer immunotherapy. Therapeutic monoclonal antibodies against these targets are currently undergoing clinical evaluation with more in pre‐clinical development; buoyed by the recent licence approval of the anti‐CTLA‐4 antibody, ipilumumab, for use in melanoma. This article will review the current status of the various antibodies and target molecules being investigated.


  • Open Access

    Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant

    by Ann L. White, Alison L. Tutt, Sonya James, Kevin A. Wilkinson, Fernanda V. V. Castro, Sandra V. Dixon, Jessica Hitchcock, Mahmood Khan, Aymen Al‐Shamkhani, Adam F. Cunningham, et al.

    Summary: In this study, we investigated the mouse dendritic cell (DC) receptor, complement receptor 4 (CR4; CD11c/CD18), as an immunotarget for triggering humoral immunity. Comparison of antibody titres generated against a panel of 13 anti‐antigen‐presenting cell receptor monoclonal antibodies, with or without conjugated ovalbumin (OVA), revealed uniquely rapid and robust responses following CR4 targeting, with antibody titres approaching 1 : 100 000 7 days after a single dose of antigen. Furthermore, using just 100 ng OVA conjugated to anti‐CD11c Fab′, we generated anti‐OVA titres greater than those produced by a 100‐fold higher dose of OVA in complete Freund’s adjuvant at day 28. These anti‐OVA antibody titres were sustained and could be boosted further with targeted OVA on day 21. Investigations to explain this vaccine potency showed that, in addition to targeting splenic DC, anti‐CDl1c antibodies delivered a powerful adjuvant effect and could boost humoral immunity against OVA even when the OVA was targeted to other molecules on DC, such as major histocompatibility complex class II, CD11a and CD11b. However, interestingly, this adjuvant effect was lost if OVA was targeted to other cells such as B cells via CD21 or CD19. The adjuvant effect was mediated through a marked enhancement of both germinal centre and extrafollicular plasma cell formation in responding spleens. These results demonstrate that anti‐CD11c monoclonal antibody can both target antigen and act as a powerful adjuvant for rapid and sustained antibody responses. They also point to an interesting role for CR4 on DC in triggering B cells during humoral immunity.


  • Open Access

    Microscopic Intratumoral Dosimetry of Radiolabeled Antibodies Is a Critical Determinant of Successful Radioimmunotherapy in B-Cell Lymphoma

    by Yong Du, Jamie Honeychurch, Martin Glennie, Peter Johnson, Tim Illidge

    Radioimmunotherapy is a highly effective treatment for some hematologic malignancies; however, the underlying mechanisms of tumor clearance remain poorly understood. We have previously shown that both targeted radiation using 131I-labeled anti–MHC class II (MHCII) monoclonal antibody (mAb) plus mAb signaling with unlabeled anti-idiotype are required for the long-term clearance of tumor in syngeneic murine lymphoma models. In this study, we have investigated how the microdistribution of the targeted radiation component of this combination affects the long-term clearance of lymphoma. 131I-labeled mAb targeting CD45 and MHCII antigens was found to deliver similar doses of radiation to tumor-bearing organ using conventional dosimetry (∼1.0 Gy per MBq when 131I was labeled to 500 μg mAb and given i.v. per mouse), but when used as radiation vectors in combination therapy only, 131I-anti-MHCII plus anti-idiotype produced long-term survival. The profound differences in therapy did not seem to be dependent on levels of 131I-mAb tumor-binding or antibody-dependent cytotoxicity. Instead, the microscopic intratumoral dosimetry seemed to be critical with the 131I-anti-MHCII, delivering more concentrated and therefore substantially higher radiation dose to tumor cells. When the administered activity of 131I-anti-CD45 was increased, a radiation dose response was shown in the presence of anti-idiotype and long-term survival was seen. We believe that these new insights should influence the selection of new antigen targets and the design of dosimetric methods in radioimmunotherapy of lymphoma. [Cancer Res 2007;67(3):1335–43]


    • 1 September 2003
      • Vol. 63  (17) , 5480-9

    CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.

    by H T Claude Chan, David Hughes, Ruth R French, Alison L Tutt, Claire A Walshe, Jessica L Teeling, Martin J Glennie, Mark S Cragg

    Rituximab is routinely used for the treatment of neoplasia, although the mechanism of action remains uncertain. In the current study, CD20-induced apoptosis was investigated with a panel of anti-CD20 monoclonal antibodies (mAb) in a wide range of cell lines. A hierarchy of mAb activity was apparent, with the B1 mAb generally the most potent. Apoptosis through CD20 was dependent on the nature of mAb binding and correlated with the extent of homotypic cell adhesion induced. However, using anti-CD20 mAb, which vary in the extent to which they redistribute wild-type and mutant CD20 molecules to membrane rafts, we showed that CD20-induced apoptosis was independent of translocation to TX-100 insoluble rafts. Using crmA-transfected cells and caspase inhibitors, we showed that phosphatidylserine translocation and mitochondrial permeability transition evoked during CD20-induced apoptosis appeared caspase independent. Furthermore, in cytoplasts which lack mitochondria and in Bcl(2)-transfected cells, phosphatidylserine was still translocated to the cell surface after CD20 stimulation. Together, these data imply that CD20 can evoke apoptosis without the involvement of mitochondria and caspases and irrespective of redistribution into TX-100 insoluble membrane rafts.


  • The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis

    by Mark S. Cragg, H. T. Claude Chan, Mathew D. Fox, Alison Tutt, Aimée Smith, David G. Oscier, Terry J. Hamblin, Martin J. Glennie

    The B-cell receptor (BCR) for antigen is composed of surface immunoglobulin (sIg), which provides antigen specificity, and a noncovalently associated signaling unit, the CD79a/b heterodimer. Defects in CD79 can influence both BCR expression and signaling and may explain why cells from certain malignancies, such as B-chronic lymphocytic leukemia (B-CLL), often express diminished and inactive BCR. Recently, an alternative transcript of CD79b (ΔCD79b) has been reported that is up-regulated in B-CLL and may explain this diminished BCR expression. Here we assess the expression of ΔCD79b in B-CLL and other lymphoid malignancies and investigate its function. High relative expression of ΔCD79b was confirmed in most cases of B-CLL and found in 6 of 6 cases of splenic lymphomas with villous lymphocytes (SLVLs) and hairy cell leukemia. In a range of Burkitt lymphoma cell lines, expression of ΔCD79b was relatively low but correlated inversely with the ability of the BCR to signal apoptosis when cross-linked by antibody (Ab). Interestingly, when Ramos-EHRB cells, which express low ΔCD79b, were transfected with this transcript, they were transformed from being sensitive to anti-Fcμ–induced apoptosis to being highly resistant. Although ΔCD79b was expressed as protein, its overexpression did not reduce the level of cell surface BCR. Finally, we showed that the inhibitory activity of ΔCD79b depended on an intact leader sequence to ensure endoplasmic reticulum (ER) trafficking and a functional signaling immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic tail. These results point to ΔCD79b being a powerful modulator of BCR signaling that may play an important role in normal and malignant B cells.


  • Open Access

    Monoclonal Antibody Therapy of B Cell Lymphoma: Signaling Activity on Tumor Cells Appears More Important Than Recruitment of Effectors

    by Alison L. Tutt, Ruth R. French, Timothy M. Illidge, Jamie Honeychurch, Harry M. McBride, Christine A Penfold, Douglas T. Fearon, R Michael E Parkhouse, Gerry G. B. Klaus, Martin J. Glennie

    Despite the recent success of mAb in the treatment of certain malignancies, there is still considerable uncertainty about the mechanism of action of anti-cancer Abs. Here, a panel of rat anti-mouse B cell mAb, including Ab directed at surface IgM Id, CD19, CD22, CD40, CD74, and MHC class II, has been investigated in the treatment of two syngeneic mouse B cell lymphomas, BCL1 and A31. Only three mAb were therapeutically active in vivo, anti-Id, anti-CD19, and anti-CD40. mAb to the other Ags showed little or no therapeutic activity in either model despite giving good levels of surface binding and activity in Ag-dependent cellular cytotoxicity and complement assays, and in some cases inhibiting cell growth in vitro. We conclude that the activity of mAb in vitro does not predict therapeutic performance in vivo. Furthermore, in vivo tracking experiments using fluorescently tagged cells showed that anti-Id and anti-CD40 mAb probably operate via different mechanisms: the anti-Id mAb cause growth arrest that is almost immediate and does not eliminate cells over a period of 5 or 6 days, and the anti-CD40 mAb have a delayed effect that allows tumor to grow normally for 3 days, but then abruptly eradicates lymphoma cells. This work supports the belief that mAb specificity is critical to therapeutic success in lymphoma and that, in addition to any effector-recruiting activity they may possess, in vivo mAb operate via mechanisms that involve cross-linking and signaling of key cellular receptors.


  • Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome

    by Jamie Honeychurch, Andrew Cruise, Alison L. Tutt, M. J. Glennie

    Despite the success of mAb and bispecific (bs)Ab in the treatment of certain malignancies, there is still considerable uncertainty about the most appropriate format in which they should be used. In the current work we have investigated a panel of bsAb [IgG and F(ab)2] with dual specificity for T cells and neoplastic B cells. Throughout this work, anti-CD2 or anti-CD3 were used to bind the mouse T cells, and antibodies to surface IgM idiotype (Id), CD19, CD22, or MHC class II were used to target mouse B cell lymphomas BCL1 or A31. In vitro, killing was measured in a conventional cytotoxicity assay using 51Cr-labelled A31 and BCL1 cells as targets and activated mouse splenocytes as effectors. bsAb showed a wide range of cytotoxic activities, which could be ranked in the following order: [anti-CD3×anti-class-II]>[anti-CD3×anti-CD19] >[anti-CD3×anti-Id]>[anti-CD3×anti-CD22], with the [anti-CD2×anti-Id] derivative showing relatively little cytotoxic activity. This hierarchy of activity indicates some correlation with the binding activity of the bsAb on target cells, but showed a much stronger parallel with the tendency of the anti-(target cells) mAb to undergo antigenic modulation (less modulation, more killing). In vivo, the situation was completely different and only the anti-ld derivatives, [anti-CD3×anti-ld] and [anti-CD2×anti-ld], were effective in prolonging the survival of tumour-bearing animals. Under optimal conditions Id-positive tumour was eradicated with a single treatment of bsAb. We conclude from this work that the target cell specificity of a bsAb is critical in determining therapeutic outcome and that in vitro cytotoxicity assays do not predict in vivo activity.